MRZ-99030

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 527611

CAS#: 1123071-24-8

Description: MRZ-99030, also known as EG-030, is an Aβ aggregation modulator potentially for the treatment of glaucoma. MRZ-99030 is a dipeptide that modulates Aβ1-42 aggregation by triggering a non-amyloidogenic aggregation pathway, thereby reducing the amount of intermediate toxic soluble oligomeric Aβ species.


Chemical Structure

img
MRZ-99030
CAS# 1123071-24-8

Theoretical Analysis

MedKoo Cat#: 527611
Name: MRZ-99030
CAS#: 1123071-24-8
Chemical Formula: C15H19N3O3
Exact Mass: 289.14
Molecular Weight: 289.335
Elemental Analysis: C, 62.27; H, 6.62; N, 14.52; O, 16.59

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: MRZ-99030; MRZ 99030; MRZ99030; EG-030; EG030; EG 030

IUPAC/Chemical Name: (R)-2-(2-amino-3-(1H-indol-3-yl)propanamido)-2-methylpropanoic acid

InChi Key: SHAXSXUDZJSSCN-LLVKDONJSA-N

InChi Code: InChI=1S/C15H19N3O3/c1-15(2,14(20)21)18-13(19)11(16)7-9-8-17-12-6-4-3-5-10(9)12/h3-6,8,11,17H,7,16H2,1-2H3,(H,18,19)(H,20,21)/t11-/m1/s1

SMILES Code: CC(C)(NC([C@H](N)CC1=CNC2=C1C=CC=C2)=O)C(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 289.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Rammes G, Gravius A, Ruitenberg M, Wegener N, Chambon C, Sroka-Saidi K, Jeggo R, Staniaszek L, Spanswick D, O'Hare E, Palmer P, Kim EM, Bywalez W, Egger V, Parsons CG. MRZ-99030 - A novel modulator of Aβ aggregation: II - Reversal of Aβ oligomer-induced deficits in long-term potentiation (LTP) and cognitive performance in rats and mice. Neuropharmacology. 2015 May;92:170-82. doi: 10.1016/j.neuropharm.2014.12.037. PubMed PMID: 25637092.

2: Parsons CG, Ruitenberg M, Freitag CE, Sroka-Saidi K, Russ H, Rammes G. MRZ-99030 - A novel modulator of Aβ aggregation: I - Mechanism of action (MoA) underlying the potential neuroprotective treatment of Alzheimer's disease, glaucoma and age-related macular degeneration (AMD). Neuropharmacology. 2015 May;92:158-69. doi: 10.1016/j.neuropharm.2014.12.038. PubMed PMID: 25634238.

3: Salt TE, Nizari S, Cordeiro MF, Russ H, Danysz W. Effect of the Aβ aggregation modulator MRZ-99030 on retinal damage in an animal model of glaucoma. Neurotox Res. 2014 Nov;26(4):440-6. doi: 10.1007/s12640-014-9488-6. PubMed PMID: 25106883.